COAGHemab Therapeutics Holdings, Inc.

Healthcare
$31.60

The financials

Hemab Therapeutics Holdings, Inc. by the numbers

The next results filing is expected around Nov 10, 2026, a quarter after the last one.

Hemab Therapeutics Holdings, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$26M−$17Mn/a
Net income−$24M−$15Mn/a
Diluted EPS−$0.80−$16.18n/a

Biotechnology

The closest names by size in the same industry

Compare peers
IMTX+0.61%
Immatics N.V.
AVLN-0.31%
Avalyn Pharma Inc.
JBIO+1.9%
Jade Biosciences, Inc.
ORIC-0.08%
Oric Pharmaceuticals, Inc.
SVRA+1.7%
Savara Inc.
MNKD-3.5%
MannKind Corporation